Abstract: Triple-negative breast cancer is a special type of breast cancer that lacks expression of oestrogen receptors, progesterone receptor, human epidermal growth factor receptor-2. Compared with other breast cancer subtypes, triple-negative breast cancer generally has the clinical characteristic of poorer prognosis, higher aggressiveness, higher metastatic and higher rates of relapse. The treatment of triple-negative breast cancer in early stage has primarily consisted of anthracycline and taxane chemotherapy in recent years, however it is prone to drug resistance. Moreover, certain targeted medicines and endocrine treatment agents are not highly sensitive against triple-negative breast cancer. Therefore, this article briefly discusses the development of combination medications and novel therapies to provide suggestions for future medications, in addition to introducing the current clinical medications used in triple-negative breast cancer.